Example: Heart Attack

Search clinical trials for: Girls Can...Move!

Total 6088 results

NCT03706547

Unknown

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Multiple Myeloma in Relapse | Multiple Myeloma Progression
NCT02456350

Unknown

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia
NCT00413400

Completed

Study of TNF-Antagonism in the Metabolic Syndrome (II)

Metabolic Syndrome
NCT00503503

Completed

Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in Japan

Rheumatoid Arthritis
NCT07594548

Not yet recruiting

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Locally Advanced Gastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8
NCT07218510

Recruiting

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
NCT06015880

Recruiting

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

High Grade B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
NCT05950464

Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma | Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma
NCT04071236

Recruiting

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-Resistant Prostate Carcinoma
NCT06179888

Suspended

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Multiple Myeloma
NCT03375307

Active, not recruiting

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Metastatic Bladder Carcinoma | Advanced Bladder Carcinoma | Advanced Genitourinary System Carcinoma | Metastatic Genitourinary System Carcinoma
NCT03367741

Active, not recruiting

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

Recurrent Endometrial Carcinoma | Advanced Endometrial Carcinoma | Metastatic Endometrial Carcinoma | Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 | Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
NCT02079740

Active, not recruiting

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
NCT01116648

Active, not recruiting

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Ovarian Endometrioid Adenocarcinoma | Fallopian Tube Carcinoma | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Ovarian Serous Surface Papillary Adenocarcinoma
NCT04320888

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma
NCT05691504

Active, not recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary Peritoneal Carcinoma | Advanced Endometrial Carcinoma | Metastatic Endometrial Carcinoma | Metastatic Platinum-Resistant Ovarian Carcinoma | Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
NCT05538897

Active, not recruiting

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recurrent Endometrial Endometrioid Adenocarcinoma | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Metastatic Endometrial Endometrioid Adenocarcinoma
NCT04750954

Active, not recruiting

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Neuroendocrine Neoplasm
NCT04557956

Active, not recruiting

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8
NCT04571879

Recruiting

Nebulized Lidocaine and Intranasal Midazolam for NGT Insertion in Children

Procedural Pain | Procedural Anxiety
NCT06984783

Completed

Visual Health Evaluation of New Designed Blue-blocking Glasses

Blue-blocking Glasses
NCT04418219

Withdrawn

Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma | Refractory Breast Carcinoma
NCT00333632

Withdrawn

Effect of Dexmedetomidine Upon Sleep Postoperatively

Sleep
NCT06852222

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) (cAMeLot-2)

Leukemia, Myeloid, Acute
NCT06394622

Recruiting

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors

Solid Tumor
NCT05702853

Recruiting

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Chronic Lymphocytic Leukemia | B-cell Non Hodgkin Lymphoma
NCT05016063

Not yet recruiting

Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute
NCT04666168

Recruiting

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Non-hodgkin's Lymphoma
NCT06698744

Withdrawn

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
NCT04150887

Active, not recruiting

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (ELEVATE)

Leukemia, Myeloid, Acute
NCT03945812

Completed

Platelet-Rich Plasma vs. Granulocyte Colony-Stimulating Factor vs. Placebo and Outcomes in Frozen Embryo Transfer

Infertility | Frozen Embryo Transfer (FET)
NCT05070754

Completed

Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca

Verruca Vulgaris | Molluscum Contagiosum Skin Infection
NCT04214886

Active, not recruiting

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

B-Cell Acute Lymphoblastic Leukemia, Adult | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent
NCT01732913

Terminated

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (Yosemite)

Indolent Non-Hodgkin's Lymphomas
NCT01050998

Completed

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis
NCT01004081

Completed

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Breast Cancer
NCT01835912

Completed

Chronic Versus Acute Dosing of Sodium Citrate for Swimming 200m

Alkalosis
NCT00606164

Unknown

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease

Alzheimer's Disease
NCT07064564

Not yet recruiting

iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers (iSTEP-N)

Opioid Use Disorder
NCT06757140

Recruiting

Opioid Drug Interaction Study

Drug Interactions | Drug Kinetics
NCT05450718

Recruiting

Low-dose Buprenorphine Initiation for Opioid Use Disorder

Opioid Use Disorder
NCT07221565

Enrolling by invitation

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT) (QSIT)

Multiple Sclerosis | Autoimmune Diseases | Rheumatoid Arthritis | Systemic Lupus Erythematosus | Immune Dysregulation | Chronic Inflammatory Syndromes
NCT06216132

Completed

Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults

Opioid Use Disorder
NCT05458609

Completed

Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep

Alcohol Use Disorder
NCT06907355

Completed

CHAO Tos: Codeina, HederA Helix, LevOdropropizina Para la TOS (CHAO TOS)

Upper Resp Tract Infection
NCT00527475

Completed

Ranibizumab and Reduced Fluence PDT for AMD (RAP)

Macular Degeneration
NCT03396276

Enrolling by invitation

Houston Emergency Opioid Engagement System (HEROES)

Opioid Use Disorder
NCT06716749

Completed

Effectiveness of Adding Morphine to Intraosseous Vancomycin for Pain Control in Total Knee Arthroplasty

Knee Osteoarthritis | Primary Total Knee Arthroplasty | Intraosseous Morphine Injection
NCT00658320

Completed

Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids

Kidney Transplantation
NCT00555321

Terminated

Belatacept in Liver Transplant Recipients

Immunosuppression in Solid Organ Transplant

Search clinical trials for: Girls Can...Move!

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations